

1635
PATENT

DTT/1500/01/10 10 NOV 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Didier Branellec et al.

Examiner: To Be Assigned

Art Unit: To Be Assigned

Application No.: **09/787,995**

Filed: **09/23/1999**

Title: **USE OF SPECIFIC HYBRID
PROMOTERS FOR CONTROLLING
EXPRESSION IN TISSUES**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

Nov. 12, 2002
Date of Deposit

Debra Coughlin
Signature

RECEIVED

DEC 30 2002

TECH CENTER 1600/2900

AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

In response to the Notice of Defective Response mailed October 11, 2002 in the above-referenced application, applicants request that the originally filed specification be amended to replace the originally filed sequence listing with the attached sequence listing. On November 11, 2002, Applicants filed a Computer Readable Form of the attached sequence listing by means of the USPTO's electronic filing service. The electronic filing also included the required statements that the paper sequence listing and the CRF are identical and neither includes any new matter. A copy of the electronic filing receipt and the Notification of Defective Response are also attached.

Respectfully submitted,

F. Aaron Dubberley

F. Aaron Dubberley, Reg. No. 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3737
Telefax: 908-231-2626

Docket No. ST98032